NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Celaid Therapeutics

Celaid Therapeutics

Private
TokyoHealthcare & Life Scienceshttps://celaidtx.com/

Last Round

Series B

Oct 7, 2025

Total Funding Raised

$37.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Celaid Therapeutics is a biotechnology company that develops a proprietary platform for the large-scale, ex vivo expansion of human hematopoietic stem cells for use in cell and gene therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

hematopoietic stem cellsHSCcell therapy manufacturingex vivo expansioncell expansion platformregenerative medicinechemically defined mediabioprocessingCDMOcell culture reagentsgene therapybiotech manufacturinglab-grown cellsbiotech licensingcell therapy scale-up

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Celaid Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Celaid Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Celaid Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 7, 2025
Series A ExtensionOct 31, 2024
GrantSep 30, 2024
Series A ExtensionMay 8, 2024
GrantMar 22, 2024
Series A
Oct 25, 2022

Key People

Founding team and executive leadership

Nobuyuki Arakawa

President CEO

Executive Team

Yusuke Inoue

Board Director, COO CFO

Executive Team

Celaid Therapeutics Investors

Notable investors and investment history

Celaid Therapeutics investors
InvestorRounds
Japan Agency for Medical Research and DevelopmentSeries B
Kobe University CapitalSeries A Extension
UTEC (The University of Tokyo Edge Capital Partners)Series B, Series A, Pre Seed, Series A Extension
Joyo Capital PartnersSeries A Extension, Series B
SBI Regional Revitalization Support CorporationSeries A
Osaka University Venture Capital Co., Ltd.Series A, Series B, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 20, 2025

    Selected for the Shonan Health Innovation Conference in Boston.

  • Oct 25, 2025

    Attending the 2025 AABB/Cord Blood Connect event in San Diego.

Celaid Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Celaid Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Celaid Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTokyo
Employee Range16
Year Founded2020
Last FundingOct 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.